130793-30-5

Basic information

• Product Name: (2S,3S,5S)-2-Hexyl-3,5-dihydroxyhexadecanoic Acid
• Synonyms: (2S,3S,5S)-2-Hexyl-3,5-dihydroxyhexadecanoic Acid ;[2S-(2R*,3R*,5R*)]-;Orlistat IMpurity M3;(2S,3S,5S)-2-Hexyl-3,5-dihydroxyhexadecanoic Acid (See H295855, SodiuM Salt)
• CAS NO: 130793-30-5
• Molecular Formula: C22H44O4
• Molecular Weight: 372.58236
• Product Categories: Aliphatics;Chiral Reagents;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Aliphatics, Chiral Reagents, Metabolites & Impurities, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 130793-30-5.mol

Chemical Properties

• Melting Point: 61-63°C
• Boiling Point: 526.706°C at 760 mmHg
• Flash Point: 286.419°C
• Appearance: /
• Density: 0.974g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.479
• Storage Temp.: Hygroscopic, -20?C Freezer, Under Inert Atmosphere
• Solubility: Chloroform, Methanol
• CAS DataBase Reference: (2S,3S,5S)-2-Hexyl-3,5-dihydroxyhexadecanoic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3S,5S)-2-Hexyl-3,5-dihydroxyhexadecanoic Acid(130793-30-5)
• EPA Substance Registry System: (2S,3S,5S)-2-Hexyl-3,5-dihydroxyhexadecanoic Acid(130793-30-5)

Safety Data

• Hazardous Substances Data: 130793-30-5(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Solid

Uses

Orlistat (O686500) impurity M3.

InChI:InChI=1/C22H44O4/c1-3-5-7-9-10-11-12-13-14-16-19(23)18-21(24)20(22(25)26)17-15-8-6-4-2/h19-21,23-24H,3-18H2,1-2H3,(H,25,26)/t19-,20?,21-/m0/s1

Upstream product

• 68711-33-1 (3S,4S,6S)-3-Hexyl-3,4,5,6-tetrahydro-4-hydroxy-6-undecyl-2H-pyran-2-one 
• 96829-58-2 Tetrahydrolipstatin 
• 104872-04-0 Orlistat 

Downstream Products

• 104871-99-0 (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one 
• 1072902-84-1 (3S,4S)-3-hexyl-4-[(2S)-2-[(triisopropylsilyl)oxy]tridecyl]oxetan-2-one 

Relevant articles and documents

One-step modification to identify dual-inhibitors targeting both pancreatic triglyceride lipase and Niemann-Pick C1-like 1

Pancreatic triglyceride lipase (PTL) and Niemann-Pick C1-like 1 (NPC1L1) have been identified as attractive therapeutic targets for obesity and hypercholesteremia, respectively. Obesity and hypercholesteremia usually co-exist, however no dual-inhibitors against PTL and NPC1L1 were reported for the treatment of obesity patients with hypercholesteremia so far. In this work, molecular hybridization-based one-step modification screening identified a potent dual-inhibitor against PTL and NPC1L1. Compound P1-11 has IC50 values of 2.1 μM against PTL through covalent binding, as well as significantly reduces cholesterol absorption in a non-competitive inhibitory manner. Molecule docking and molecular dynamics studies revealed the reason of its activity to both PTL and NPC1L1. Moreover, the gene and protein expression levels of PTL and NPC1L1 were also determined respectively after the treatment of P1-11. Development of dual-inhibitors against PTL and NPC1L1 could provide novel treatment options for obesity patients with hypercholesteremia. The results of current research would great support the development of dual-inhibitors against PTL and NPC1L1.

Tetrahydrolipstatin: Thermal and hydrolytic degradation

The thermal and hydrolytic degradation of tetrahydrolipstatin (THL, 1) was investigated. All main degradation products were isolated, characterized, and synthesized. Labile intermediates unavailable to isolation were detected and identified by GC/MS analysis of their silylated derivatives, and whenever possible, compared with independently prepared reference compounds. The identified degradation products represent at least 97% of the total degradation mixture. Two main reaction pathways are proposed. Pharmacological data are reported for the degradation mixture and the main degradation products.